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Transnational Organisations increasingly prioritise the need to support local research capacity in low and
middle income countries in order that local priorities are addressed with due consideration of contextual
issues. There remains limited evidence on the best way in which this should be done or the ways in which
external agencies can support this process.
We present an analysis of the learning from the INDOX Research Network, established in 2005 as a
partnership between the Institute of Cancer Medicine at the University of Oxford and India’s top nine
comprehensive cancer centres. INDOX aims to enable Indian centres to conduct clinical research to the
highest international standards; to ensure that trials are developed to address the specific needs of Indian
patients by involving Indian investigators from the outset; and to provide the training to enable them to
design and conduct their own studies. We report on the implementation, outputs and challenges of
simultaneously trying to build capacity and deliver meaningful research output.
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C
ancer is now the second leading cause of death in
low- and middle-income countries and by 2030 it
is estimated that 70% of all cancer cases will be in
developing countries with potentially devastating con-
sequences, both in terms of death and suffering as well as
the huge financial costs which could overwhelm health-
care budgets (1). India, with a population of over one
billion and an overstretched public health system is
particularly vulnerable to this epidemic and its conse-
quences. Although life expectancy in India has doubled
since independence, it still has the largest disease burden
of any country (2) and is experiencing rapid demo-
graphic, socioeconomic and risk-factor changes, parti-
cularly in urban areas, leading to an alarming rise in
the incidence of cancer and other Non-communicable
diseases (35).
Cancer is already the second leading cause of death in
India and the incidence is expected to double in the next
10 years to 2 million cases a year (1, 4). Patients also
usually have to cover the costs of treatment from their
own pockets leading to increased poverty and even
medical bankruptcies (5).
However, the ability to tackle this epidemic has been
severely hampered by the lack of infrastructure and
experience in clinical research (6, 7). Despite WHO’s
declaration in 2004 that: ‘Well planned health research is
fundamental to the improvement of health in all coun-
tries’ (8), the reality remains that the vast majority of
clinical research continues to be designed and conducted
on the small minority of the world’s population living in
high-income countries (See Fig. 1) (9, 10). Specifically, of
32,346 studies currently being conducted in cancer, only
365 (1%) are in India despite it having 17% of the
world’s population and 10% of the global cancer burden
(9). The evidence base (both for the effectiveness of
treatments and the importance of risk factors) as well as
the capacity to conduct research in all LMICs, including
India, is grossly inadequate (11, 12).
The results of trials conducted under optimal condi-
tions in high-income countries may not always be
applicable to populations in LMICs and could precipitate
a massive upsurge in the prescribing of costly drugs with
limited clinical utility and in healthcare systems which are
already financially overstretched. Furthermore, aside
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regimens between healthcare systems, patient safety
may also be compromised. This risk is particularly
prominent in therapeutic trials of cancer chemotherapy
and novel biologic therapies, which can have potentially
life-threatening side effects. To transport current best
practice from the oncology clinics of high-income coun-
tries and use them in less developed healthcare systems
may not only lack efficacy but could ultimately cost lives.
Inequalities in healthcare can be further perpetuated by
incentives for pharmaceutical companies to develop
therapies for affluent, largely White populations from
richer nations. With personalised medicine becoming a
reality in oncology, we risk relegating the ethnicities
concentrated in developing countries to an even lower
standard of care (14). This potential ethnic prejudice can
only be addressed by ensuring that clinical research is
conducted in all populations.
Clinical trials in India
Although the number of clinical trials conducted in India
has increased rapidly over the last 10 years, the vast
majority of these had been commissioned and designed
outside of India with little or no input from local
investigators and are not designed to answer research
questions of primary relevance to local populations,
using India simply as a place to recruit extra patients
(13, 14). Clearly, in order for research to have maximal
benefits to the local population, it is essential that
local investigators are involved in the design and conduct
of these studies. For example, cancer of the gall
bladder is one of the most common cancers in women
in India with a very poor prognosis but relatively under-
studied by virtue of its concentration in low-income
countries (15).
Indian centres had very limited experience in conduct-
ing clinical trials prior to 2005 and although the Principle
Investigators (PIs) had some experience, training of more
junior staff as well as research nurses and trial pharma-
cists had been far more limited. Building longer term
capacity and sustainability was also a major problem
as funding was provided by the sponsor only for the
duration of the study and the trial co-ordinator, once
trained, would then move on to another job.
In this article, we outline our experience in building
and sustaining research capacity at both an individual
and institutional level through the establishment of a
clinical research network in India and describe the many
challenges we faced and how we have tried to overcome
them.
The INDOX Cancer Research Network
The INDOX (INDiaOxford) Cancer Research Network
was established in 2005 as a unique academic-industry
partnership between the Institute for Cancer Medicine at
Oxford University, six leading cancer centres in India.
The network has now expanded to 12 centres (See Fig. 2).
Our primary objectives were to enable Indian centres to
conduct clinical research to the highest international
standards; to ensure that trials were developed to address
Fig. 1. Geographical distribution of clinical research studies in cancer (10).
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INDOX Scientific Review Board
INDOX Coordinating Centre, Oxford Industry partner
INDOX Sites in India
Eight tumour specific 
research committees 
Industry partner drafts concept protocol
Send to Indox Co-ordinating Centre (ICC) 
ICC send to INDOX scientific review board for 
review and internal discussion
Reviewers send response to ICC
INDOX investigator(s) draft concept protocol
Send to Indox Co-ordinating Centre (ICC) and for 
review by Scientific Review Board
ICC send to industry partner for review and internal 
discussion
Reviewers send response to ICC
ICC collate responses and work with industry partner and 
scientific review board to develop full protocol
Industry initiated Investigator initiated
Fig. 3. Organisation of INDOX network and development of clinical trial protocols.
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Challenges How they were overcome Outcome
Limited experience in clinical trials prior to 2005 as India not
bound by WTO/IPR rules and Indian pharma industry had
focussed on development of generics.
Worked with industry partners to place clinical trials in India
and thereby gain experience and build capacity for research.
Twenty-one trials conducted over last six years mainly in
breast, head & neck, gastric and colorectal cancer.
No experience in Phase I trials as these were not allowed
India prior to 2005.
Provided practical and theoretical training in conducting
Phase 1 trials in Oxford and India.
Conducted one of the first Phase 1 trial in India from 2007 to
2009.
Lack of training opportunities, especially at the level of junior
faculty, research nurses and pharmacists.
Provided a comprehensive training programme for all staff
involved in clinical trials covering GCP, etc.
‘Train the trainers’ programme for principle investigators and
site co-ordinators.
To date more than 100 PIs, coordinators and research nurses
etc. attended training courses in Oxford and India.
This is supplemented by distance learning through online
courses.
GCP (Good Clinical Practice) only became part of Indian law
in 2005 and centres in India did not have quality assurance
standards in place.
Standard Operating Procedures (SOPs) not in use in clinical
trials units and those provided by industry not designed for
use in Indian context.
All sites assessed for inclusion in network and monitored
annually for quality assurance and compliance with GCP.
Developed India-specific SOPs in collaboration with Indian
sites.
Uniform quality standards with appropriate SOPs
implemented across all sites.
Monitoring has shown high quality trial practice and
adherence to GCP and FDA audits have been passed.
Almost no experience of collaborative research with the vast
majority of studies being small, single-centre studies and
therefore often underpowered.
INDOX brought many investigators together for the first time
to jointly design and conduct clinical studies, developing
relationships through annual meetings and quarterly
telephone conferences.
A condition of taking studies forward for support is that they
must be multi-centric and studies are now conducted across
all 12 sites.
PIs extremely busy with service and administration
commitments.
Large number of patients seen in each clinic making it difficult
to devote time to explain trials to patients properly and
ensure informed consent.
Appointed and trained dedicated site coordinators/research
support officers whose role it is to support the PIs in all
aspects of managing trials.
PIs have more time to spend explaining trial to patient and
more time to work on actually designing and conducting their
own trials.
Significant delays in gaining regulatory approval from Ministry
of health Regulatory system, particularly for early phase trials.
Worked closely with Drugs Controller General of India to
improve understanding of, and need for Phase 1 trials in
India.
Successful in gaining regulatory approval for one of the first
multinational Phase 1 trials in India.
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8the specific needs of Indian patients by involving Indian
investigators from the outset; and to provide the training
to enable them to design and conduct their own studies.
We decided that it was important to work with industry
from the outset, not just to fund the network but also
because we could benefit from their expertise and
experience in clinical research. It provided the means to
sustain the network in the early years while we were
building capacity after which time we were confident we
would no longer be reliant on their funding. Most
importantly, the funds enabled us to involve Indian
investigators in developing a cancer research strategy
for India which would ensure that protocols were
developed for those cancers which had the greatest
burden and the greatest unmet medical need.
Organisation and governance
INDOX’s governance structure was organised as an equal
partnership, with joint leadership and joint development
of research protocols. A Scientific Review Board was
established which included all Indian PIs as well as
representatives from Oxford. The review board worked
with investigators and industry to develop both industry
and investigator initiated trials according to the work-
flow expressed in Fig. 3. Eight tumour specific research
committees, each chaired by a senior Indian PI, were
then responsible for developing investigator-initiated
protocols.
Challenges, solutions and progress to date
In trying to build research capacity to design and execute
epidemiological and clinical trials, we encountered a
number of challenges at both the individual and institu-
tional level. We present them here with the belief that
such challenges and the solutions we implemented will
have many commonalities with future similar pro-
grammes (see Table 1).
All sites now have dedicated clinical trials units and
trained clinical research staff and are equipped to conduct
trials to international (ICH-GCP) standards. Since 2005,
INDOX has conducted 21 clinical trials in a number of
different cancers, including one of the first multinational
Phase 1 trials to be approved by the Indian regulatory
authorities. From 20052007, all studies were industry
sponsored with no Indian PIs but as the capacity,
experience and expertise of the network increased, so the
balance has shifted decisively to investigator initiated
studies and in 2012, all INDOX studies will be led by
Indian PIs, either working with industryor independently.
Ethical concerns
There continues to be a great deal of concern about the
ethics of conducting clinical trials in India due to
inadequate regulatory oversight and the potential risks
of inadequately informed consent, inducement and ex-
ploitation, particularly of the poor and illiterate (13, 16).
In recognition of these challenges we only work with
public or not-for-profit institutions which have indepen-
dent ethics committees. We also assessed all centres
before joining the network for compliance with ICH-
GCP guidelines and provide training in the ethical
conduct of clinical research on a continuing basis to all
new and existing staff. We found that many of the
informed consent forms (ICFs) for industry-sponsored
trials were incomprehensible to many participants and
therefore worked with colleagues in India to develop
templates and SOPs to ensure that ICFs used appropriate
language and terminology for the local context.
Due to the difficultyof ensuring that those who agree to
take part in trials are both fully informed of, and under-
stand, the risks and benefits of doing so, we are also
conducting an audit of consent procedures to assess the
motivation of clinical trial participants and to see how
informed their consent really is. This study is being
conducted in all Indian centres which are conducting
clinical trials within the network and will help us to
identify specific aspects of the consent process that require
emphasis or fine-tuning to suit the requirements of Indian
subjects. Furthermore, we hope that through this study we
will be able to confirm or dispel the prevailing doubts that
Indian patients are being exploited.
Conclusions and next steps
Over the past six years, INDOX has achieved many of its
initial aims and objectives and has shown how research
networks can be developed and sustained through aca-
demic-industry collaborations to the benefit of both
parties (Fig. 4). However, much remains to be done,
particularly in relation to prevention, early detection and
developing affordable treatments which are accessible to
even the poorest in India. To this end, we developed the
ASCOLT trial in collaboration with the National Cancer
centre in Singapore, a randomised controlled trial of
Aspirin in the secondary prevention of colorectal cancer
“The biggest benefit for India has been that INDOX has brought all these
cancer centres together. India is a vast country and has different religions
and languages. INDOX has brought us together – there have been meetings,
we understand each other better and it has standardised the cancer care in
many of these centres and allowed the training of a lot of junior people.”
Fig. 4. Professor Vinod Raina, All India Institute of Medical Sciences (AIIMS) New Delhi.
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Asia. We have also recently started the largest and first
national study to investigate potentially modifiable risk
factors for eight common cancers in India, the INDOX
case-control consortium (17).
Although INDOX’s activities to date have been con-
fined to cancer in India, the model can be applied to any
therapeutic or geographical area. We are therefore now
establishing a similar network (building capacity for
research in cancer and diabetes) across the Middle East,
another region with a rapidly increasing burden of cancer
and other NCDs but with limited clinical research
experience and capacity (10).
INDOX is an innovative model for NorthSouth
cooperation in building capacity for clinical research
and we believe that similar models could be successful in
helping to tackle cancer and NCDs in other developing
countries.
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